|
|
|
| Relationship between MGMT and Tiam1 Expression in Patients with Brain Metastases from NSCLC Treated with Concurrent Intensity-modulated Radiotherapy Combined with Temozolomide |
| CHAI Lixia, WANG Rong, YANG Shirong, et al |
| The Fifth People's Hospital of Qinghai,Xining Qinghai 810000,China |
|
|
|
|
Abstract Objective: To analyze the relationship between the efficacy of concurrent radiotherapy combined with temozolomide and the expression of O6 methylguanine DNA methyltransferase (Mgmt) and invasion and metastasis inducing factor 1 (Tiam1) in patients with brain metastases from non-small cell lung cancer (NSCLS).Methods: 60 NSCLC patients with brain metastasis were treated with simultaneous modulated accelerated radiotherapy and temozolomide,which of the expression of MGMT and Tiam1 in lung tissue was detected by immunohistochemistry and the relationship between the expression of MGMT and Tiam1 and the therapeutic effect and the survival time were analyzed.Results: The relief rate (RR) of 21 patients with MGMT (+) and Tiam1 (+) was 76.19%,the disease control rate (DCR) of which was 95.23%;The RR of 16 patients with MGMT (+) and Tiam1 (-) were 25.00%,the DCR of which was 81.25%;The RR of 17 patients with MGMT (-) and Tiam1 (-) were 88.24%,the DCR of which was 94.12%;The RR of 6 patients with MGMT (-) and Tiam1 (-) were 33.33%,and the DCR of which was 66.6% 7%.The follow-up time of 60 patients ranged from 1 to 45.35 months,the median follow-up time was 16.75 months and the median survival time was 13 months,where the 1-year,2-year and 3-year survival rates were 75.01%,53.86% and 25.31%,respectively.The median survival time of 21 patients with MGMT (+) and Tiam1 (+) was 13 months,where the 1-year,2-year and 3-year survival rates were 64.32%,45.15% and 20.33%,respectively.The median survival time of 16 patients with MGMT (+) and Tiam1 (-) was 6 months,where the 1-year,2-year and 3-year survival rates were 33.69%,20.01% and 0.00%,respectively.The median survival time of 17 patients with MGMT (-) and Tiam1 (+) was 15 months,where the 1-year,2-year and 3-year survival rates were 92.05%,74.12% and 40.09%,respectively.The median survival time of 6 patients with MGMT (-) and Tiam1 (-) was 10 months,where the 1-year,2-year and 3-year survival rates were 55.63%,47.35% and 18.96%,respectively.Conclusion: The different expression of MGMT and Tiam1 in lung cancer is related to the therapeutic effect of simultaneous modulated accelerated radiotherapy combined with temozolomide on NSCLS patients with brain metastasis.
|
|
|
|
|
|
[1] 王宝红,郭守娟,张丹丹,等.替莫唑胺联合放疗治疗非小细胞肺癌脑转移的效果观察[J].河南医学研究,2017(18):36~38.
[2] 李家伟,肖雯艳.替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移瘤的效果观察[J].广西医科大学学报,2018,35(7):980~983.
[3] Han W,Wang L,Zhang L,et al.Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593-3p/CCND2 and miR-653-5p/TIAM1 pathways in non-small cell lung cancer[J].Biochem Biophys Res Commun,2019,510(3):462~466.
[4] 杨舒一,单飞,施裕新,张志勇.晚期肺癌免疫治疗现状及影像学疗效评价和预测[J].中国临床医学,2019,26(4):641~646.
[5] Singh R,Lehrer EJ,Ko S,et al.Brain metastases from non-small cell lung cancer with EGFR or ALK mutations:a systematic review and meta-analysis of multidisciplinary approaches[J].Radiother Oncol,2019,144:165~179.
[6] Churilla TM,Weiss SE.Emerging trends in the management of brain metastases from non-small cell lung cancer[J].Curr Oncol Rep,2018,20(7):54.
[7] 吕晓平,张秋迟.非小细胞肺癌脑转移调强放射治疗的临床有效性探讨[J].黑龙江医药科学,2018,41(1):70~71.
[8] 苏雷,胡玲,崔桂敏,等.MGMT及IDH1表达与替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移疗效的关系[J].重庆医学,2017,46(21):2976~2979.
[9] 项振飞,方建晨,林丽,等.非小细胞肺癌脑转移患者全脑放疗效果及预后影响因素分析[J].浙江医学,2018,40(21):2325~2329. |
|
|
|
2020, Vol. 26 
